Non-hallucinogenic neuroplastogens are being developed as a potentially safer alternative to psychedelics, with a lower risk of hallucinations. Enveric Biosciences is developing a derivative designed to preserve signaling associated with therapeutic neuroplasticity while potentially reducing hallucinogenic risk.

While plastic surgery experts noted genetics play a key role in individual aging, they suggested Moore’s fresh face could also be attributed to a strict routine of advanced cosmetic treatments. Dr. Tia Liu, MD MSc, who has not personally treated the actress, told RadarOnline.com the “uniform luminosity people notice typically comes from consistent medical grade […]

In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court. This week, Enveric Biosciences announced that a Post Grant Review petition filed against its U.S. Patent No. 12,138,276 has been formally withdrawn. The petition, initially filed by Gilgamesh Pharmaceuticals, was later inherited by AbbVie Inc. following AbbVie’s acquisition […]

Enveric Biosciences Inc. (NASDAQ:ENVB) on Wednesday said that the previously announced Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals Inc. against Enveric’s issued U.S. Patent No. 12,138,276 (the ‘276 patent) has been withdrawn. The action follows Enveric’s filing of a Request for Discretionary Denial of the petition. As a result, there are no remaining challenges […]

Enveric Biosciences reported new mechanistic data showing that its lead neuropsychiatric candidate EB-003 engages both Gq and β-arrestin signaling downstream of the 5-HT2A receptor, based on proprietary bioluminescence resonance energy transfer assays. The disclosure comes as the U.S.-based biotechnology firm advances EB-003 through IND-enabling studies with the stated goal of developing a non-hallucinogenic neuroplastogenic therapy […]

For much of the past decade, the psychedelic renaissance has revolved around experience. Carefully supervised psilocybin sessions. Structured integration. Regulatory pathways built around high-touch therapeutic models. But beneath that narrative, a deeper scientific shift has been taking shape. The real engine of change may not be the subjective trip at all, but the intracellular signaling […]

In recent years, interest in the therapeutic potential of psychedelics — including psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) — has surged. Clinical trials have increasingly reported positive therapeutic and safety outcomes, fueling significant investment and the rapid emergence of a psychedelic industry. Hundreds of biotech and pharmaceutical companies have launched over […]

In results announced this morning, Enveric reported new mechanistic findings from proprietary bioluminescence resonance energy transfer, or BRET, assays evaluating its lead candidate, EB-003. The data show that EB-003 activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT2A receptor, a key molecular target associated with psychedelic compounds.

Enveric Biosciences (NASDAQ:ENVB) on Thursday shared new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor. EB-003 is being developed to be a non-hallucinogenic neuroplastogen intended to support streamlined treatment paradigms, including potential at-home administration.

For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise for conditions ranging from depression and anxiety to post-traumatic stress disorder (PTSD), but there is still a potential downside.